Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
NCT00038428
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Ovarian Neoplasms
Interventions
DRUG:
TLK286
Sponsor
Telik